Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study

Alexandra Gomez-Arteaga, Rory Shallis, Mariam Nawas, Landi Guo, Temitope Oloyede, Kwang Woo Ahn, Veronika Bachanova, Michael Byrne, Sergio Giralt, Lohith Gowda, Ann Jakubowski, Mark Litzow, Filippo Milano, Kristin Page, Wael Saber, Nelli Bejanyan, Larisa Broglie, Xinjie Xu, Jean Yared

Blood (2025) 146 (Supplement 1): 1060.

https://doi.org/10.1182/blood-2025-1060

Published: 2025

Journal Articles

Fludarabine pharmacokinetic model identifies an optimal exposure associated with improved outcomes in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 113.

https://doi.org/10.1182/blood-2025-113

Published: 2025

Journal Articles

Limitations of the IWG-MRT/ELN response criteria in defining post-transplant remission and clinical success in patients with myelofibrosis: A retrospective study

Charlotte Hughes, Brian Shaffer, Sergio Giralt, Esperanza Papadopoulos, Ann Jakubowski, Doris Ponce, Boglarka Gyurkocza, Miguel-Angel Perales, Roni Tamari

Blood (2025) 146 (Supplement 1): 2506.

https://doi.org/10.1182/blood-2025-2506

Published: 2025

Journal Articles

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Blood (2025) 146 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2025-3723

Published: 2025

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV + lymphomas after allogeneic hematopoietic cell transplantation

Blood (2012) 119 (11): 2644–2656.

https://doi.org/10.1182/blood-2011-08-371971

Published: 2012

Includes: Supplemental data

Journal Articles

A Phase I Dose Escalation Trial of Donor T Cells Sensitized with Pentadecapeptides of the CMV-pp65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants.

Guenther Koehne, MD, PhD, Ekaterina Doubrovina, MD, PhD, Aisha Hasan, MD, Juliet Barker, MBBS, H.R. Castro-Malaspina, MD, Miguel Perales, MD, Ann Jakubowski, PhD, MD, Esperanza B Papadopoulos, MD, James W. Young, MD, Farid Boulad, MD, Trudy N Small, MD, Susan E Prockop, MD, Nancy A. Kernan, MD, Andromachi Scaradavou, MD, Genovefa Papanicolaou, Marcel van den Brink, MD, PhD, Richard J O'Reilly, MD

Blood (2009) 114 (22): 2262.

https://doi.org/10.1182/blood.V114.22.2262.2262

Published: 2009

Journal Articles

Early Immune Recovery Predicts Overall and Disease-Free Survival After Allogeneic Hematopoietic Stem Cell Transplantation.

Jenna D. Goldberg, MD, Junting Zheng, MA, Juliet Barker, MBBS, Farid Boulad, MD, H.R. Castro-Malaspina, MD, Katharine C Hsu, MD, PhD, Ann Jakubowski, MD, PhD, Nancy Kernan, MD, Richard J O'Reilly,, MD, Esperanza Papadopoulos, MD, Susan Prockop, MD, Andromachi Scaradavou, MD, Marcel van den Brink, MD, PhD, James Young, MD, Glenn Heller, PhD, Miguel-Angel Perales, MD

Blood (2009) 114 (22): 2222.

https://doi.org/10.1182/blood.V114.22.2222.2222

Published: 2009

Journal Articles

Disease-Free Survival After Cord Blood (CB) Transplantation Is Not Different to That After Related or Unrelated Donor Transplantation in Patients with Hematologic Malignancies.

Blood (2009) 114 (22): 2296.

https://doi.org/10.1182/blood.V114.22.2296.2296

Published: 2009

Journal Articles

Phase II Trial of a Chemotherapy-Only Regimen of Busulfan, Melphalan, Fludarabine and R-ATG Followed by Allogeneic T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplants (HSCT) for the Treatment of Myeloid Malignancies.

Farid Boulad, MD, Ann Jakubowski, MD, Esperanza Papadopoulos, MD, Katharine C. Hsu, MD, Miguel Angel Perales, MD, Marcel van den Brink, MD, James W. Young, MD, Michelle Chiu, Nancy A. Kernan, MD, Susan E. Prockop, MD, Andromachi Scaradavou, MD, Trudy N. Small, MD, Hugo Castro-Malaspina, MD, Richard J. O’Reilly, MD

Blood (2007) 110 (11): 2991.

https://doi.org/10.1182/blood.V110.11.2991.2991

Published: 2007

Journal Articles

Pilot Trial of Rituximab for the Prevention of Epstein Barr Virus B Cell Lymphoproliferative Disorder (EBV-LPD) Following T Cell Depleted (TCD) Unrelated or HLA-Mismatched Related Hematopoietic Stem Cell Transplantation.

Trudy N. Small, MD, Nancy A. Kernan, MD, Ann Jakubowski, MD, PhD, James W. Young, MD, Susan Prockop, MD, Miguel-Angel Perales, MD, Richard J. O’Reilly, MD, Esperanza B. Papadopoulos, MD

Blood (2006) 108 (11): 2922.

https://doi.org/10.1182/blood.V108.11.2922.2922

Published: 2006

Journal Articles

Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants

Dana Jaffe, Esperanza B. Papadopoulos, James W. Young, Richard J. O'Reilly, Susan Prockop, Nancy A. Kernan, Ann Jakubowski, Farid Boulad, Miguel-Angel Perales, Hugo Castro-Malaspina, Trudy N. Small

Blood (2006) 108 (7): 2470–2475.

https://doi.org/10.1182/blood-2006-04-006981

Published: 2006

Journal Articles

PCR Screening for Epstein-Barr Virus-Related Lymphoproliferative Disease (EBV-LPD) among Allogeneic Stem Cell Transplant (AlloSCT) Recipients: The Importance of T Cell Depletion.

Giannina Garces Ambrossi, Ann Jakubowski, MD, PhD, Carrie Brennan, Timothy E. Kiehn, PhD, David M. Weinstock, MD

Blood (2005) 106 (11): 3234.

https://doi.org/10.1182/blood.V106.11.3234.3234

Published: 2005

Journal Articles

Response to Immunizations Following Allogeneic HCT with Adjuvant Rituximab Therapy.

Mary Pao, MD, PhD, Esperanza B. Papadopoulos, MD, Farid Boulad, MD, Hugo Castro-Malaspina, MD, Ann Jakubowski, MD, PhD, Nancy A. Kernan, MD, Miguel Perales, MD, Susan Prockop, MD, Ruth Ford, RN, James W. Young, MD, Richard J. O’Reilly, MD, Trudy N. Small, MD

Blood (2005) 106 (11): 3242.

https://doi.org/10.1182/blood.V106.11.3242.3242

Published: 2005

Journal Articles

Response to Hepatitis B Vaccination Following Allogeneic Hematopoietic Cell Transplantation (HCT).

Trudy N. Small, MD, Esperanza B. Papadopoulos, MD, Farid Boulad, MD, Hugo Castro-Malaspina, MD, Ann Jakubowski, MD, PhD, Nancy A. Kernan, MD, Miguel Perales, MD, Susan Prockop, MD, James W. Young, MD, Richard J. O’Reilly, MD, Dana Jaffe, MPH

Blood (2005) 106 (11): 83.

https://doi.org/10.1182/blood.V106.11.83.83

Published: 2005

Journal Articles

Growth Potential of Human Leukemia Blast Cells in SCID Mice and Association with Prognosis of Human Acute Leukemias.

Ying Yan, M.D., Ph. D, Peter Steinherz, M.D., Xiuqin Guan, M.D., Ann Jakubowski, M.D., Joesph P. McGuirk, M.D., Richard J. O’Reilly, M.D.

Blood (2004) 104 (11): 1900.

https://doi.org/10.1182/blood.V104.11.1900.1900

Published: 2004

Journal Articles

A Phase II Trial of Busulfan, Melphalan, and Fludarabine followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants from HLA-Identical, or HLA-Non Identical Related or Unrelated Donors for the Treatment of Advanced Hematopoietic Malignancies.

Farid Boulad, MD, Ann Jakubowski, MD, Hugo Castro-Malaspina, MD, Katharine C. Hsu, MD, Nancy A. Kernan, MD, Esperanza B. Papadopoulos, MD, Miguel A. Perales, MD, Susan E. Prockop, MD, Trudy N. Small, MD, Marcel R.M. van den Brink, MD, James W. Young, MD, Michelle Ro, Nancy Collins, PhD, Richard J. O’Reilly, MD

Blood (2004) 104 (11): 1822.

https://doi.org/10.1182/blood.V104.11.1822.1822

Published: 2004

Journal Articles

Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines

Andrea König, Laura Wrazel, Raymond P. Warrell, Jr, Roberta Rivi, Pier Paolo Pandolfi, Ann Jakubowski, Janice L. Gabrilove

Blood (1997) 90 (2): 562–570.

https://doi.org/10.1182/blood.V90.2.562

Published: 1997

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study

Fludarabine pharmacokinetic model identifies an optimal exposure associated with improved outcomes in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide

Limitations of the IWG-MRT/ELN response criteria in defining post-transplant remission and clinical success in patients with myelofibrosis: A retrospective study

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV + lymphomas after allogeneic hematopoietic cell transplantation

A Phase I Dose Escalation Trial of Donor T Cells Sensitized with Pentadecapeptides of the CMV-pp65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants.

Early Immune Recovery Predicts Overall and Disease-Free Survival After Allogeneic Hematopoietic Stem Cell Transplantation.

Disease-Free Survival After Cord Blood (CB) Transplantation Is Not Different to That After Related or Unrelated Donor Transplantation in Patients with Hematologic Malignancies.

Phase II Trial of a Chemotherapy-Only Regimen of Busulfan, Melphalan, Fludarabine and R-ATG Followed by Allogeneic T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplants (HSCT) for the Treatment of Myeloid Malignancies.

Pilot Trial of Rituximab for the Prevention of Epstein Barr Virus B Cell Lymphoproliferative Disorder (EBV-LPD) Following T Cell Depleted (TCD) Unrelated or HLA-Mismatched Related Hematopoietic Stem Cell Transplantation.

Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants

PCR Screening for Epstein-Barr Virus-Related Lymphoproliferative Disease (EBV-LPD) among Allogeneic Stem Cell Transplant (AlloSCT) Recipients: The Importance of T Cell Depletion.

Response to Immunizations Following Allogeneic HCT with Adjuvant Rituximab Therapy.

Response to Hepatitis B Vaccination Following Allogeneic Hematopoietic Cell Transplantation (HCT).

Growth Potential of Human Leukemia Blast Cells in SCID Mice and Association with Prognosis of Human Acute Leukemias.

A Phase II Trial of Busulfan, Melphalan, and Fludarabine followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants from HLA-Identical, or HLA-Non Identical Related or Unrelated Donors for the Treatment of Advanced Hematopoietic Malignancies.

Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only